NPORT-EX 2 70E1TRPUSEQResearchFd.htm e1troweusequityresearchfund9.htm - Generated by SEC Publisher for SEC Filing

T. ROWE PRICE U.S. EQUITY RESEARCH FUND
September 30, 2020 (Unaudited)

Portfolio of Investments  Shares/Par  $ Value 
(Cost and value in $000s)     
COMMON STOCKS 99.5%     
COMMUNICATION SERVICES 11.6%     
 
Diversified Telecommunication Services 1.1%     
AT&T  938,111  26,746 
Verizon Communications  403,445  24,001 
    50,747 
Entertainment 1.9%     
Activision Blizzard  26,954  2,182 
Electronic Arts (1)  99,292  12,949 
Netflix (1)  91,243  45,624 
Walt Disney  191,413  23,750 
    84,505 
Interactive Media & Services 6.3%     
Alphabet, Class A (1)  39,997  58,620 
Alphabet, Class C (1)  69,820  102,607 
Facebook, Class A (1)  480,736  125,905 
    287,132 
Media 2.0%     
Charter Communications, Class A (1)  29,521  18,431 
Comcast, Class A  1,211,059  56,024 
DISH Network, Class A (1)  30,088  873 
Liberty Broadband, Class C (1)  120,528  17,220 
    92,548 
Wireless Telecommunication Services 0.3%     
T-Mobile US (1)  96,023  10,981 
    10,981 
Total Communication Services    525,913 
CONSUMER DISCRETIONARY 12.0%     
 
Auto Components 0.4%     
Aptiv  87,277  8,001 
Magna International  166,111  7,600 
    15,601 
 
   
The accompanying notes are an integral part of this Portfolio of Investments.   

 


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Automobiles 0.2%     
Ferrari  58,292  10,731 
    10,731 
Hotels, Restaurants & Leisure 2.0%     
Darden Restaurants  23,345  2,352 
Hilton Worldwide Holdings  105,331  8,987 
Marriott International, Class A  111,320  10,306 
McDonald's  156,782  34,412 
Starbucks  141,235  12,135 
Wynn Resorts  134,846  9,683 
Yum! Brands  133,258  12,166 
    90,041 
Internet & Direct Marketing Retail 5.5%     
Amazon. com (1)  74,518  234,637 
Booking Holdings (1)  9,781  16,732 
    251,369 
Multiline Retail 0.4%     
Dollar General  65,315  13,691 
Dollar Tree (1)  65,245  5,960 
    19,651 
Specialty Retail 2.6%     
AutoZone (1)  5,834  6,871 
Burlington Stores (1)  17,676  3,643 
CarMax (1)  85,832  7,889 
Home Depot  154,565  42,924 
Lowe's  103,527  17,171 
O'Reilly Automotive (1)  29,132  13,432 
Ross Stores  131,347  12,257 
TJX  160,574  8,936 
Ulta Beauty (1)  13,666  3,061 
    116,184 
Textiles, Apparel & Luxury Goods 0.9%     
NIKE, Class B  278,265  34,933 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
VF  104,439  7,337 
    42,270 
Total Consumer Discretionary    545,847 
CONSUMER STAPLES 6.2%     
 
Beverages 1.8%     
Coca-Cola  646,662  31,925 
Keurig Dr Pepper  349,131  9,636 
Monster Beverage (1)  92,233  7,397 
PepsiCo  247,552  34,311 
    83,269 
Food & Staples Retailing 1.0%     
Costco Wholesale  74,275  26,368 
Walmart  145,638  20,376 
    46,744 
Food Products 1.0%     
Conagra Brands  464,013  16,570 
Mondelez International, Class A  403,966  23,208 
Tyson Foods, Class A  110,592  6,578 
    46,356 
Household Products 1.4%     
Kimberly-Clark  65,736  9,707 
Procter & Gamble  378,786  52,647 
    62,354 
Personal Products 0.1%     
Estee Lauder, Class A  12,456  2,719 
    2,719 
Tobacco 0.9%     
Altria Group  415,570  16,058 
Philip Morris International  321,276  24,092 
    40,150 
Total Consumer Staples    281,592 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
ENERGY 2.0%     
 
Energy Equipment & Services 0.2%     
Halliburton  778,494  9,381 
    9,381 
Oil, Gas & Consumable Fuels 1.8%     
Chevron  221,920  15,978 
Concho Resources  137,263  6,056 
ConocoPhillips  423,172  13,897 
Enbridge  191,071  5,579 
EOG Resources  244,689  8,794 
Exxon Mobil  378,194  12,984 
Hess  120,186  4,919 
Marathon Petroleum  143,856  4,221 
Pioneer Natural Resources  18,281  1,572 
Targa Resources  111,754  1,568 
TOTAL, ADR  193,475  6,636 
    82,204 
Total Energy    91,585 
FINANCIALS 9.5%     
 
Banks 3.4%     
Bank of America  1,725,393  41,565 
Fifth Third Bancorp  1,242,045  26,480 
First Republic Bank  68,648  7,487 
Huntington Bancshares  989,717  9,076 
JPMorgan Chase  49,179  4,734 
PNC Financial Services Group  236,373  25,980 
Wells Fargo  1,649,083  38,770 
    154,092 
Capital Markets 2.2%     
Cboe Global Markets  9,743  855 
Charles Schwab  49,276  1,785 
CME Group  91,070  15,237 
E*TRADE Financial  216,730  10,847 
Goldman Sachs Group  71,081  14,285 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Intercontinental Exchange  154,116  15,419 
KKR  140,896  4,839 
Morgan Stanley  215,981  10,443 
Northern Trust  31,400  2,448 
Raymond James Financial  18,880  1,374 
State Street  79,055  4,690 
TD Ameritrade Holding  271,808  10,641 
Tradeweb Markets, Class A  99,822  5,790 
    98,653 
Consumer Finance 0.7%     
Ally Financial  518,226  12,992 
Capital One Financial  241,682  17,367 
    30,359 
Diversified Financial Services 1.4%     
Berkshire Hathaway, Class B (1)  239,155  50,926 
Equitable Holdings  612,985  11,181 
Voya Financial  74,113  3,552 
    65,659 
Insurance 1.8%     
American International Group  691,990  19,050 
Chubb  200,738  23,310 
Marsh & McLennan  54,802  6,286 
MetLife  365,740  13,594 
Progressive  116,349  11,015 
Willis Towers Watson  52,394  10,941 
    84,196 
Total Financials    432,959 
HEALTH CARE 13.4%     
 
Biotechnology 2.4%     
AbbVie  535,417  46,897 
Alexion Pharmaceuticals (1)  33,630  3,848 
Amgen  102,118  25,954 
Biogen (1)  30,555  8,668 
Incyte (1)  60,812  5,457 
Regeneron Pharmaceuticals (1)  8,388  4,696 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Seattle Genetics (1)  15,200  2,975 
Vertex Pharmaceuticals (1)  42,765  11,637 
    110,132 
Health Care Equipment & Supplies 3.1%     
Abbott Laboratories  98,752  10,747 
Becton Dickinson & Company  144,631  33,653 
Cooper  7,116  2,399 
Danaher  112,035  24,124 
Hologic (1)  132,093  8,780 
Intuitive Surgical (1)  53,526  37,979 
Medtronic  48,576  5,048 
Stryker  88,875  18,519 
    141,249 
Health Care Providers & Services 2.7%     
Anthem  55,619  14,939 
Centene (1)  287,973  16,797 
Cigna  118,309  20,043 
CVS Health  137,128  8,008 
HCA Healthcare  82,149  10,242 
Humana  29,791  12,330 
McKesson  14,312  2,132 
UnitedHealth Group  128,287  39,996 
    124,487 
Life Sciences Tools & Services 1.1%     
Agilent Technologies  146,977  14,836 
Thermo Fisher Scientific  79,287  35,007 
    49,843 
Pharmaceuticals 4.1%     
AstraZeneca, ADR  125,859  6,897 
Elanco Animal Health (1)  783,564  21,885 
Eli Lilly  224,434  33,221 
Johnson & Johnson  273,331  40,693 
Merck  314,787  26,112 
Novartis, ADR  30,960  2,692 
Pfizer  574,575  21,087 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Sanofi, ADR  144,188  7,234 
Zoetis  149,886  24,787 
    184,608 
Total Health Care    610,319 
INDUSTRIALS & BUSINESS SERVICES 8.0%     
 
Aerospace & Defense 1.3%     
Boeing  140,104  23,154 
L3Harris Technologies  68,589  11,649 
Northrop Grumman  15,916  5,021 
Raytheon Technologies  24,750  1,424 
Teledyne Technologies (1)  30,165  9,358 
Textron  265,169  9,570 
    60,176 
Air Freight & Logistics 1.0%     
FedEx  73,271  18,429 
United Parcel Service, Class B  167,415  27,896 
    46,325 
Airlines 0.2%     
Alaska Air Group  85,567  3,134 
United Airlines Holdings (1)  140,945  4,898 
    8,032 
Building Products 0.2%     
Johnson Controls International  238,129  9,727 
    9,727 
Commercial Services & Supplies 0.2%     
Waste Connections  106,571  11,062 
    11,062 
Industrial Conglomerates 1.4%     
General Electric  2,398,102  14,940 
Honeywell International  173,156  28,504 
Roper Technologies  47,772  18,875 
    62,319 
Machinery 2.4%     
Cummins  106,696  22,530 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Flowserve  217,645  5,940 
Fortive  123,209  9,390 
Illinois Tool Works  24,623  4,757 
Ingersoll Rand (1)  277,427  9,876 
Otis Worldwide  153,894  9,606 
PACCAR  207,210  17,671 
Parker-Hannifin  38,766  7,844 
Snap-on  22,879  3,366 
Stanley Black & Decker  82,535  13,387 
Wabtec  99,425  6,153 
    110,520 
Professional Services 0.5%     
CoStar Group (1)  7,163  6,078 
Equifax  75,581  11,859 
TransUnion  30,064  2,529 
    20,466 
Road & Rail 0.8%     
JB Hunt Transport Services  66,090  8,352 
Norfolk Southern  21,518  4,605 
Union Pacific  117,147  23,063 
    36,020 
Total Industrials & Business Services    364,647 
INFORMATION TECHNOLOGY 29.2%     
 
Communications Equipment 0.9%     
Cisco Systems  760,064  29,939 
Motorola Solutions  64,718  10,148 
    40,087 
Electronic Equipment, Instruments & Components 0.5%     
Amphenol, Class A  141,423  15,312 
CDW  51,326  6,135 
Keysight Technologies (1)  19,168  1,893 
    23,340 
IT Services 6.6%     
Accenture, Class A  129,472  29,259 
Broadridge Financial Solutions  5,908  780 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Cognizant Technology Solutions, Class A  217,021  15,066 
Fidelity National Information Services  223,766  32,941 
Fiserv (1)  319,336  32,908 
FleetCor Technologies (1)  72,613  17,289 
Global Payments  147,243  26,147 
Leidos Holdings  73,707  6,571 
Mastercard, Class A  149,370  50,512 
PayPal Holdings (1)  53,120  10,466 
Snowflake, Class A (1)  15,432  3,873 
VeriSign (1)  47,520  9,735 
Visa, Class A  328,267  65,644 
    301,191 
Semiconductors & Semiconductor Equipment 5.7%     
Advanced Micro Devices (1)  397,047  32,554 
Applied Materials  303,180  18,024 
Broadcom  6,106  2,225 
Lam Research  106,780  35,424 
Marvell Technology Group  7,059  280 
Maxim Integrated Products  31,600  2,136 
Micron Technology (1)  680,708  31,966 
Monolithic Power Systems  15,445  4,319 
NVIDIA  145,633  78,819 
QUALCOMM  291,631  34,319 
Teradyne  28,700  2,281 
Xilinx  149,335  15,567 
    257,914 
Software 8.7%     
Citrix Systems  55,734  7,675 
Intuit  61,322  20,004 
Microsoft  1,245,933  262,057 
NortonLifeLock  975,934  20,338 
Oracle  127,436  7,608 
salesforce. com (1)  247,856  62,291 
Synopsys (1)  30,740  6,578 
Workday, Class A (1)  52,287  11,249 
    397,800 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Technology Hardware, Storage & Peripherals 6.8%     
Apple  2,681,549  310,550 
    310,550 
Total Information Technology    1,330,882 
MATERIALS 2.3%     
 
Chemicals 1.8%     
Celanese  63,370  6,809 
CF Industries Holdings  102,076  3,135 
DuPont de Nemours  195,291  10,835 
Linde  119,356  28,422 
PPG Industries  109,069  13,315 
RPM International  35,679  2,956 
Sherwin-Williams  13,201  9,198 
Westlake Chemical  112,345  7,102 
    81,772 
Containers & Packaging 0.4%     
Avery Dennison  54,641  6,985 
International Paper  112,650  4,567 
Packaging Corp. of America  40,404  4,406 
Sealed Air  68,949  2,676 
Westrock  47,600  1,654 
    20,288 
Metals & Mining 0.1%     
Freeport-McMoRan  317,299  4,962 
    4,962 
Total Materials    107,022 
REAL ESTATE 2.2%     
EQUITY REAL ESTATE INVESTMENT TRUSTS 2.2%     
Alexandria Real Estate Equities, REIT  31,723  5,076 
American Tower, REIT  71,910  17,383 
AvalonBay Communities, REIT  61,993  9,258 
Crown Castle International, REIT  33,334  5,550 
Equinix, REIT  17,547  13,338 
Equity Residential, REIT  98,402  5,051 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U. S. EQUITY RESEARCH FUND

 
 
 
  Shares/Par  $ Value 
(Cost and value in $000s)     
 
Essex Property Trust, REIT  14,394  2,890 
JBG SMITH Properties, REIT  41,525  1,110 
Prologis, REIT  198,315  19,955 
SBA Communications, REIT  5,027  1,601 
Simon Property Group, REIT  73,614  4,761 
SL Green Realty, REIT  75,684  3,510 
Welltower, REIT  103,452  5,699 
Weyerhaeuser, REIT  206,663  5,894 
Total Real Estate    101,076 
UTILITIES 3.1%     
 
Electric Utilities 1.5%     
American Electric Power  124,093  10,142 
Duke Energy  73,217  6,484 
Entergy  50,588  4,984 
NextEra Energy  90,429  25,100 
Southern  411,686  22,322 
    69,032 
Gas Utilities 0.2%     
Atmos Energy  71,689  6,853 
    6,853 
Multi-Utilities 1.4%     
Ameren  254,211  20,103 
NiSource  298,668  6,570 
Public Service Enterprise Group  177,599  9,752 
Sempra Energy  228,718  27,071 
    63,496 
Total Utilities    139,381 
Total Common Stocks (Cost $3,393,879)    4,531,223 
 
SHORT-TERM INVESTMENTS 0.4%     
MONEY MARKET FUNDS 0.4%     
 
T. Rowe Price Treasury Reserve Fund, 0.12% (2)(3)  16,002,994  16,003 
    16,003 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U.S. EQUITY RESEARCH FUND

  Shares/Par    $ Value 
(Cost and value in $000s)       
U. S. TREASURY OBLIGATIONS 0.0%       
U. S. Treasury Bills, 0.11%, 3/25/21 (4)  1,460,000    1,459 
      1,459 
Total Short-Term Investments (Cost $17,462)      17,462 
Total Investments in Securities 99.9%       
(Cost $3,411,341)    $  4,548,685 
Other Assets Less Liabilities 0.1%      4,406 
Net Assets 100.0%    $  4,553,091 

 

  Shares/Par and Notional Amount are denominated in U. S. dollars unless 
    otherwise noted. 
(1 )  Non-income producing 
(2 )  Seven-day yield 
(3 )  Affiliated Companies 
(4 )  At September 30, 2020, all or a portion of this security is pledged as collateral 
    and/or margin deposit to cover future funding obligations. 
ADR   American Depositary Receipts 
REIT   A domestic Real Estate Investment Trust whose distributions pass-through 
    with original tax character to the shareholder 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U.S. EQUITY RESEARCH FUND

  FUTURES CONTRACTS            
($ 000 s)           
            Value and 
      Expiration  Notional    Unrealized Gain 
      Date  Amount    (Loss)
 
  Long, 104 S&P 500 E-Mini Index Contracts   12/20  17,430  $    64 
  Net payments (receipts) of variation margin to date           31 
 
  Variation margin receivable (payable) on open futures contracts      $  95 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U.S. EQUITY RESEARCH FUND

Affiliated Companies
($000s)

The fund may invest in certain securities that are considered affiliated companies. As defined
by the 1940 Act, an affiliated company is one in which the fund owns 5% or more of the
outstanding voting securities, or a company that is under common ownership or control. The
following securities were considered affiliated companies for all or some portion of the nine
months ended September 30, 2020. Net realized gain (loss), investment income, change in net
unrealized gain/loss, and purchase and sales cost reflect all activity for the period then ended.

        Change in Net       
    Net Realized Gain    Unrealized    Investment  
Affiliate      (Loss)    Gain/Loss    Income  
T. Rowe Price Treasury Reserve               
Fund    $  —#  $    $  72 + 
 
 
Supplementary Investment Schedule             
    Value  Purchase  Sales    Value  
Affiliate    12/31/19  Cost  Cost    9/30/20  
T. Rowe Price Treasury                 
Reserve Fund  $  16,750    ¤  ¤$    16,003 ^ 

 

#  Capital gain distributions from mutual funds represented $0 of the net realized gain (loss) . 
+  Investment income comprised $72 of dividend income and $0 of interest income. 
¤  Purchase and sale information not shown for cash management funds. 
^  The cost basis of investments in affiliated companies was $16,003. 

 

The accompanying notes are an integral part of this Portfolio of Investments.


 

T. ROWE PRICE U.S. EQUITY RESEARCH FUND
Unaudited
NOTES TO PORTFOLIO OF
INVESTMENTS

T. Rowe Price U.S. Equity Research Fund, Inc. (the fund) is registered under the Investment Company Act of 1940 (the
1940 Act) as an open-end management investment company and follows accounting and reporting guidance of the
Financial Accounting Standards Board Accounting Standards Codification Topic 946. The accompanying Portfolio of
Investments was prepared in accordance with accounting principles generally accepted in the United States of America
(GAAP). For additional information on the fund’s significant accounting policies and investment related disclosures,
please refer to the fund’s most recent semiannual or annual shareholder report and its prospectus.

VALUATION

The fund’s financial instruments are valued at the close of the New York Stock Exchange (NYSE), normally 4 p.m. ET,
each day the NYSE is open for business.

Fair Value
The fund’s financial instruments are reported at fair value, which GAAP defines as the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The T. Rowe Price Valuation Committee (the Valuation Committee) is an internal committee that has been
delegated certain responsibilities by the fund’s Board of Directors (the Board) to ensure that financial instruments are
appropriately priced at fair value in accordance with GAAP and the 1940 Act. Subject to oversight by the Board, the
Valuation Committee develops and oversees pricing-related policies and procedures and approves all fair value
determinations. Specifically, the Valuation Committee establishes procedures to value securities; determines pricing
techniques, sources, and persons eligible to effect fair value pricing actions; oversees the selection, services, and
performance of pricing vendors; oversees valuation-related business continuity practices; and provides guidance on
internal controls and valuation-related matters. The Valuation Committee reports to the Board and has representation
from legal, portfolio management and trading, operations, risk management, and the fund’s treasurer.

Various valuation techniques and inputs are used to determine the fair value of financial instruments. GAAP
establishes the following fair value hierarchy that categorizes the inputs used to measure fair value:

Level 1 - quoted prices (unadjusted) in active markets for identical financial instruments that the fund can access at
the reporting date

Level 2 - inputs other than Level 1 quoted prices that are observable, either directly or indirectly (including, but not
limited to, quoted prices for similar financial instruments in active markets, quoted prices for identical or
similar financial instruments in inactive markets, interest rates and yield curves, implied volatilities, and
credit spreads)

Level 3 - unobservable inputs

Observable inputs are developed using market data, such as publicly available information about actual events or
transactions, and reflect the assumptions that market participants would use to price the financial instrument.
Unobservable inputs are those for which market data are not available and are developed using the best information
available about the assumptions that market participants would use to price the financial instrument. GAAP requires
valuation techniques to maximize the use of relevant observable inputs and minimize the use of unobservable inputs.
When multiple inputs are used to derive fair value, the financial instrument is assigned to the level within the fair value
hierarchy based on the lowest-level input that is significant to the fair value of the financial instrument. Input levels are
not necessarily an indication of the risk or liquidity associated with financial instruments at that level but rather the
degree of judgment used in determining those values.


 

T. ROWE PRICE U.S. EQUITY RESEARCH FUND

Valuation Techniques
Equity securities listed or regularly traded on a securities exchange or in the over-the-counter (OTC) market are valued
at the last quoted sale price or, for certain markets, the official closing price at the time the valuations are made. OTC
Bulletin Board securities are valued at the mean of the closing bid and asked prices. A security that is listed or traded on
more than one exchange is valued at the quotation on the exchange determined to be the primary market for such
security. Listed securities not traded on a particular day are valued at the mean of the closing bid and asked prices.
Actively traded equity securities listed on a domestic exchange generally are categorized in Level 1 of the fair value
hierarchy. OTC Bulletin Board securities, certain preferred securities, and equity securities traded in inactive markets
generally are categorized in Level 2 of the fair value hierarchy.

Debt securities generally are traded in the OTC market and are valued at prices furnished by independent pricing
services or by broker dealers who make markets in such securities. When valuing securities, the independent pricing
services consider the yield or price of bonds of comparable quality, coupon, maturity, and type, as well as prices quoted
by dealers who make markets in such securities. Generally, debt securities are categorized in Level 2 of the fair value
hierarchy; however, to the extent the valuations include significant unobservable inputs, the securities would be
categorized in Level 3.

Investments in mutual funds are valued at the mutual fund’s closing NAV per share on the day of valuation and are
categorized in Level 1 of the fair value hierarchy. Financial futures contracts are valued at closing settlement prices and
are categorized in Level 1 of the fair value hierarchy.

Thinly traded financial instruments and those for which the above valuation procedures are inappropriate or are
deemed not to reflect fair value are stated at fair value as determined in good faith by the Valuation Committee. The
objective of any fair value pricing determination is to arrive at a price that could reasonably be expected from a current
sale. Financial instruments fair valued by the Valuation Committee are primarily private placements, restricted
securities, warrants, rights, and other securities that are not publicly traded.

Subject to oversight by the Board, the Valuation Committee regularly makes good faith judgments to establish and
adjust the fair valuations of certain securities as events occur and circumstances warrant. For instance, in determining
the fair value of an equity investment with limited market activity, such as a private placement or a thinly traded public
company stock, the Valuation Committee considers a variety of factors, which may include, but are not limited to, the
issuer’s business prospects, its financial standing and performance, recent investment transactions in the issuer, new
rounds of financing, negotiated transactions of significant size between other investors in the company, relevant market
valuations of peer companies, strategic events affecting the company, market liquidity for the issuer, and general
economic conditions and events. In consultation with the investment and pricing teams, the Valuation Committee will
determine an appropriate valuation technique based on available information, which may include both observable and
unobservable inputs. The Valuation Committee typically will afford greatest weight to actual prices in arm’s length
transactions, to the extent they represent orderly transactions between market participants, transaction information can
be reliably obtained, and prices are deemed representative of fair value. However, the Valuation Committee may also
consider other valuation methods such as market-based valuation multiples; a discount or premium from market value
of a similar, freely traded security of the same issuer; or some combination. Fair value determinations are reviewed on a
regular basis and updated as information becomes available, including actual purchase and sale transactions of the
issue. Because any fair value determination involves a significant amount of judgment, there is a degree of subjectivity
inherent in such pricing decisions, and fair value prices determined by the Valuation Committee could differ from
those of other market participants. Depending on the relative significance of unobservable inputs, including the
valuation technique(s) used, fair valued securities may be categorized in Level 2 or 3 of the fair value hierarchy.


 

T. ROWE PRICE U.S. EQUITY RESEARCH FUND

Valuation Inputs
The following table summarizes the fund’s financial instruments, based on the inputs used to determine their fair values
on September 30, 2020 (for further detail by category, please refer to the accompanying Portfolio of Investments):

($000s)    Level 1  Level 2  Level 3  Total Value 
Assets           
Common Stocks  $  4,531,223$  — $  — $  4,531,223 
Short-Term Investments    16,003  1,459    17,462 
Total Securities    4,547,226  1,459    4,548,685 
Futures Contracts    95      95 
Total  $  4,547,321$  1,459$  — $  4,548,780